Antiviral drug discovery for the treatment of enterovirus 71 infections

Antiviral Research

Volumn 97, Issue 2, 2013, Pages 183-194

  Shang, Luqing ^a   Xu, Mengying ^a   Yin, Zheng ^a  

^a NANKAI UNIVERSITY   (China)

Author keywords

Antiviral therapy; Enterovirus; Enterovirus 71; Picornavirus

Indexed keywords

4',6 DICHLOROFLAVAN; ANTIVIRUS AGENT; BPR 0Z 101; BPR 0Z 103; BPR 0Z 194; LACTOFERRIN; NF 449; PLECONARIL; UNCLASSIFIED DRUG; VIRUS PROTEIN;

AMINO TERMINAL SEQUENCE; CHINA; ENTEROVIRUS 71; ENTEROVIRUS 71 INFECTION; ENTEROVIRUS INFECTION; GENOTYPE; HERPANGINA; KOREA; MORTALITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; TAIWAN; THAILAND; VIET NAM; VIRUS CLASSIFICATION; VIRUS GENOME; VIRUS MUTATION;

ANTIVIRAL AGENTS; ASIA, SOUTHEASTERN; CHINA; DRUG DISCOVERY; ENCEPHALITIS, VIRAL; ENTEROVIRUS A, HUMAN; HAND, FOOT AND MOUTH DISEASE; HUMANS;

ENTEROVIRUS; HUMAN ENTEROVIRUS 71; PICORNAVIRIDAE; RNA VIRUSES;

EID: 84871975653     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.12.005     Document Type: Review

References (151)

1. Amineva S.P., et al. Rhinovirus 3C protease precursors 3CD and 3CD' localize to the nuclei of infected cells. J. Gen. Virol. 2004, 85:2969-2979.
2. Arita M., et al. Characterization of pharmacologically active compounds that inhibit poliovirus and enterovirus71 infectivity. J. Gen. Virol. 2008, 89:2518-2530.
3. Arita M., et al. Cellular kinase inhibitors that suppress enterovirus replication have a conserved target in viral protein 3A similar to that of enviroxime. J. Gen. Virol. 2009, 90:1869-1879.
4. Arita M., et al. A bifunctional anti-enterovirus compound that inhibits replication and the early stage of enterovirus 71 infection. J. Gen. Virol. 2010, 91:2734-2744.
5. Arnold R.R., et al. A bactericidal effect for human lactoferrin. Science 1977, 197:263-265.
6. Barnard D.L., et al. In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding in hibitors with potent antipicornavirus activity. Antimicrob. Agents Chemother. 2004, 48:1766-1772.
7. Barton D.J., et al. Poliovirus RNA replication and genetic complementation in cell-free reactions. Molecular Biology of Picornaviruses 2002, 461-469. ASM Press, Washington, DC.
8. Bazan J.F., Fletterick R.J. Viral cysteine proteases are homologous to the trypsin-like family of serine proteases: structural and functional implications. Proc. Natl. Acad. Sci. USA 1988, 85:7872-7876.
9. Behnia R., Munro S. Organelle identity and the signposts for membrane traffic. Nature 2005, 438:597-604.
10. Belov G.A., et al. Poliovirus proteins induce membrane association of GTPase ADP-ribosylation factor. J. Virol. 2005, 79:7207-7216.
11. Bergmann E.M., et al. Crystal structure of an inhibitor complex of the 3C proteinase from hepatitis A virus (HAV) and implications for the polyprotein processing in HAV. J. Virol. 1999, 265:153-163.
12. Binford S.L., et al. Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor. Antimicrob. Agents Chemother. 2005, 49:619-626.
13. Birtley J.R., et al. Crystal structure of foot-and-mouth disease virus 3C protease: new insights into catalytic mechanism and cleavage specificity. J. Biol. Chem. 2005, 280:11520-11527.
14. Brown B.A., Pallansch M.A. Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus. Virus Res. 1995, 39:195-205.
15. Chan Y.F., et al. Phylogenetic designation of enterovirus 71 genotypes and subgenotypes using complete genome sequences. Infect. Genet. Evol. 2010, 10:404-412.
16. Chang C.S., et al. Design, synthesis, and antipicornavirus activity of 1-[5-(4-arylphenoxy)alkyl]-3-pyridin-4-ylimidazolidin-2-one derivatives. J. Med. Chem. 2005, 48:3522-3535.
17. Chang C.W., et al. Daphne Genkwa sieb. Et zucc. Water-soluble extracts act on enterovirus 71 by inhibiting viral entry. Viruses 2012, 4(4):539-556.
18. Chang Z.Y., et al. Selection and characterization of vaccine strain for Enterovirus 71 vaccine development. Vaccine 2012, 30:703-711.
19. Chang L.Y., et al. Outcome of enterovirus 71 infections with or without stage-based management: 1998 to 2002. Pediatr. Infect. Dis. J. 2004, 23:327-332.
20. Chang L.Y., et al. Neurodevelopment and cognition in children after enterovirus 71 infection. N. Engl. J. Med. 2007, 356:1226-1234.
21. Chen P., et al. Molecular determinants of enterovirus 71 viral entry: cleft around GLN-172 on VP1 protein interacts with variable region on scavenge receptor B2. J. Biol. Chem. 2012, 287(9):6406-6420.
22. Chen T.C., et al. Antiviral activity of pyridylimidazolidinones against enterovirus 71 variants. J. Biomed. Sci. 2008, 15:291-300.
23. Chen T.C., et al. Novel antiviral agent DTriP-22 targets RNA-dependent RNA polymerase of enterovirus 71. Antimicrob. Agents Chemother. 2009, 53:2740-2747.
24. Chern J.H., et al. Synthesis and antienteroviral activity of a series of novel, oxime ether-containing pyridyl imidazolidinones. Bioorg. Med. Chem. Lett. 2004, 14:5051-5056.
25. Chiang L.C., et al. Antiviral activities of extracts and selected pure constituents of Ocimum basilicum. Clin. Exp. Pharmacol. Physiol. 2005, 32:811-816.
26. Chiu C.H., et al. Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71. Microbes Infect. 2006, 8:1671-1678.
27. Chiu Y.H., et al. Prevention of human enterovirus 71 infection by kappa carrageenan. Antiviral Res. 2012, 95(2):128-134.
28. Choi H.J., et al. Antiviral activity of raoulic acid from Raoulia australis against picornaviruses. Phytomedicine 2009, 16:35-39.
29. Chou A.H., et al. Pilot scale production of highly efficacious and stable enterovirus 71 vaccine candidates. PLoS ONE 2012, 7(4):e34834.
30. Chung Y.C., et al. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 2008, 26:1855-1862.
31. Clark M.E., et al. Poliovirus proteinase 3C converts an active form of transcription factor IIIC to an inactive form: a mechanism for inhibition of host cell polymerase III transcription by poliovirus. EMBO J. 1991, 10:2941-2947.
32. Clark M.E., et al. Direct cleavage of human TATA-binding protein by poliovirus protease 3C in vivo and in vitro. Mol. Cell. Biol. 1993, 13:1232-1237.
33. Conti C., et al. Anti-picornavirus activity of synthetic flavon-3-yl esters. Antiviral Chem. Chemother. 1998, 9:511-515.
34. Cui S., et al. Crystal structure of human enterovirus 71 3C protease. J. Mol. Biol. 2011, 408:449-461.
35. DeClercq E., et al. New developments in anti-HIV chemotherapy. Biochem. Biophys. Acta 2002, 1587:258-275.
36. DeJong A.S., et al. Functional analysis of picornavirus 2B proteins: effects on calcium homeostasis and intracellular protein trafficking. J. Virol. 2008, 82:3782-3790.
37. DeJong A.S., et al. Mutational analysis of different regions in the coxsackievirus 2B protein: requirements for homo-multimerization, membrane permeabilization, subcellular localization, andvirus replication. J. Biol. Chem. 2004, 279:19924-19935.
38. DeJong A.S., et al. Multimerization reactions of coxsackievirus proteins 2B, 2C and 2BC: a mammalian two-hybrid analysis. J. Gen. Virol. 2002, 83:783-793.
39. DeJong A.S., et al. The coxsackievirus 2B protein increases efflux of ions from the endoplasmic reticulum and Golgi, thereby inhibiting protein trafficking through the Golgi. J. Biol. Chem. 2006, 281:14144-14150.
40. DeJong A.S., et al. Determinants for membrane association and permeabilization of the coxsackievirus 2B protein and the identification of the Golgi complex as the target organelle. J. Biol. Chem. 2003, 278:1012-1021.
41. Deng J.X., et al. The highly conserved 5' untranslated region as an effective target towards the inhibition of Enterovirus 71 replication by unmodified and appropriate 2'-modified siRNAs. J. Biomed. Sci. 2012, 19:73.
42. DePalma A.M., et al. Potential use of antiviral agents in polioeradication. Emer. Infect. Dis. 2008, 14:545-551.
43. DePalma A.M., et al. Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307. Antimicrob. Agents Chemother. 2009, 53:1850-1857.
44. DePalma A.M., et al. Selective inhibitors of picornavirus replication. Med. Res. Rev. 2008, 28:823-884.
45. Dimmock N.J., et al. The structure of virus. Introduction to Modern Virology 2001, 34-36. Blackwell Science, Oxford. 5th ed.
46. Diana G.D., et al. [[(4,5-Dihydro-2-oxazolyl)phenoxy]alkyl]isoxazoles. Inhibitors of picornavirus uncoating. J. Med. Chem. 1985, 28:1906-1910.
47. Doedens J.R., Kirkegaard K. Inhibition of cellular protein secretion by poliovirus proteins 2B and 3A. EMBO J. 1995, 14:894-907.
48. Dragovich P.S., et al. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as l-glutamine replacements. J. Med. Chem. 1999, 42:1213-1224.
49. Dragovich P.S., et al. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors.1. Michael acceptor structure-activity studies. J. Med. Chem. 1998, 41:2806-2818.
50. Falk M.M., et al. Foot-and-mouth disease virus protease 3C induces specific proteolytic cleavage of host cell histone H3. J. Virol. 1990, 64:748-756.
51. Falah, N., et al., 2012. Blocking human enterovirus 71 replication by targeting viral 2A protease. J. Antimicrob. Chemother. [Epub ahead of print].
52. Foo D.G., et al. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect. 2007, 9:1299-1306.
53. Genovese D., et al. Effect of chloro-, cyano-, and amidino-substituted flavanoids on enterovirus infection in vitro. Antiviral Res. 1995, 27:123-136.
54. Gitlin L., et al. Short interfering RNA confers intracellular antiviral immunity in human cells. Nature 2002, 418:430-434.
55. Harris K.S., et al. Purification and characterization of poliovirus polypeptide 3CD, a proteinase and a precursor for RNA polymerase. J. Virol. 1992, 66:7481-7489.
56. Heinz B.A., Vance L.M. Sequence determinants of 3A-mediated resistance to enviroxime in rhinoviruses and enteroviruses. J. Virol. 1996, 70:4854-4857.
57. Hellen C.U., et al. Determinants of substrate recognition by poliovirus 2A proteinase. J. Virol. 1992, 66:3330-3338.
58. Hogle J.M., et al. Three-dimensional structure of poliovirus at 2.9 A resolution. Science 1985, 229:1358-1365.
59. Hung H.C., et al. Inhibition of enterovirus 71 replication and the viral 3D polymerase by aurintricarboxylic acid. J. Antimicrob. Chemother. 2010, 65(4):676-683.
60. Hung H.C., et al. Synergistic inhibition of enterovirus 71 replication by interferon and rupintrivir. J. Infect. Dis. 2011, 203(12):1784-1790.
61. Huang S.W., et al. Mutations in VP2 and VP1 capsid proteins increase infectivity and mouse lethality of enterovirus 71 by virus binding and RNA accumulation enhancement. Virology 2012, 422(1):132-143.
62. Jiang, H., et al., 2011. Biochemical characterization of enterovirus 71 3D RNA polymerase. 1809, 211-219.
63. Joachims M., et al. Cleavage of poly(A)-binding protein by enterovirus proteases concurrent with inhibition of translation in vitro. J. Virol. 1999, 73:718-727.
64. Kempf B.J., Barton D.J. Poliovirus 2A(Pro) increases viral mRNA and polysome stability coordinately in time with cleavage of eIF4G. J. Virol. 2008, 82:5847-5859.
65. Ku Z., et al. Development of murine monoclonal antibodies with potent neutralization effects on enterovirus 71. J. Virol. Methods 2012, 186:193-197.
66. Kuechler E., et al. Picornavirus proteinase-mediated shutoff of host cell translation: direct cleavage of a cellular initiation factor. Molecular Biology of Picornaviruses 2002, 301-311. ASM Press, Washington, DC. B.L. Semler, E. Wimmer (Eds.).
67. Kuo C.J., et al. Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents. Bioorg. Med. Chem. 2008, 16:7388-7398.
68. Kuyumcu-Martinez N.M., et al. Efficient cleavage of ribosome-associated poly(A)-binding protein by enterovirus 3C protease. J. Virol. 2002, 76:2062-2074.
69. Kuyumcu-Martinez N.M., et al. Cleavage of poly(A)-binding protein by poliovirus 3C protease inhibits host cell translation: a novel mechanism for host translation shutoff. Mol. Cell. Biol. 2004, 24:1779-1790.
70. Lee J.C., et al. Development of a cell-based assay for monitoring specific hepatitis C virus NS3/4A protease activity in mammalian cells. Anal. Biochem. 2003, 316:162-170.
71. Lee J.C., et al. A mammalian cell-based reverse two-hybrid system for functional analysis of 3C viral protease of human enterovirus 71. Anal. Biochem. 2008, 375:115-123.
72. Li Y.P., et al. Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial. Vaccine 2012, 30(22):3295-3303.
73. Li X., et al. The C-terminal residues of poliovirus proteinase 2A(pro) are critical for viral RNA replication but not for cis- or trans-cleavage. J. Gen. Virol. 2001, 82:397-408.
74. Li Z.H., et al. Ribavirin reduces mortality in enterovirus 71-infected mice by decreasing viral replication. J. Infect. Dis. 2008, 197:854-857.
75. Lim X.F., et al. Characterization of an isotype-dependent monoclonal antibody against linear neutralizing epitope effective for prophylaxis of enterovirus 71 infection. PLoS ONE 2012, 7(1):e29751.
76. Lin J.Y., et al. Viral and host proteins involved in picornavirus life cycle. J. Biomed. Sci. 2009, 16:103-117.
77. Lin T.Y., et al. Lactoferrin inhibits enterovirus 71 infection of human embryonal rhabdomyosarcoma cells in vitro. J. Infect. Dis. 2002, 186:1161-1164.
78. Lin Y.L., et al. Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles. Vaccine 2012, 30(7):1305-1312.
79. Lin Y.W., et al. Enterovirus 71 infection of human dendritic cells. Exp. Biol. Med. 2009, 234:1166-1173.
80. Liu J., et al. Transgenic expression of human P-selectin glycoprotein ligand-1 is not sufficient for enterovirus 71 infection in mice. Arch. Virol. 2012, 157:539-543.
81. Liu J., et al. Lycorine reduces mortality of human enterovirus 71-infected mice by inhibiting virus replication. Virol. J. 2011, 8:483-492.
82. Liu J.N., et al. Combined peptides of human enterovirus 71 protect against virus infection in mice. Vaccine 2010, 28:7444-7451.
83. Liu M.L., et al. Type I interferons protect mice against enterovirus 71 infection. J. Gen. Virol. 2005, 286(12):3263-3269.
84. Lu G.W., et al. Enterovirus 71 and Coxsackievirus A16 3C proteases: binding to Rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design. J. Virol. 2011, 85:10319-10331.
85. Lu J., et al. Enterovirus 71 disrupts interferon signaling by reducing the level of interferon receptor 1. Antiviral Ther. 2011, 16(1):51-58.
86. Lu W.W., et al. Selective inhibition of enterovirus 71 replication by short hairpin RNAs. Biochem. Biophys. Res. Commun. 2004, 325:494-499.
87. Mao H.X., et al. Establishment of a cell-based assay system for hepatitis C virus serine protease and its primary applications. World J. Gastroenterol. 2003, 9:2474-2479.
88. Mao Q., et al. Comparative analysis of the immunogenicity and protective effects of inactivated EV71 vaccines in mice. PLoS ONE 2012, 7:e46043.
89. Marcotte L.L., et al. Crystal structure of poliovirus 3CD protein: virally encoded protease and precursor to the RNA-dependent RNA polymerase. J. Virol. 2007, 81:3583-3596.
90. Matthews D.A., et al. Structure of human rhinovirus 3C protease reveals a trypsin-like polypeptide fold, RNA-binding site, and means for cleaving precursor polyprotein. Cell 1994, 77:761-771.
91. Meng F.Y., et al. Tolerability and immunogenicity of an inactivated enterovirus 71 vaccine in Chinese healthy and adults and children: an open label, phase 1 clinical trial. Human Vaccine Immunother. 2012, 8:668-674.
92. Mosimann S.C., et al. Refined X-ray crystallographic structure of the poliovirus 3C gene product. J. Mol. Biol. 1997, 27(3):1032-1047.
93. Paul A.V., et al. Proteinprimed RNA synthesis by purified poliovirus RNA polymerase. Nature 1998, 393:280-284.
94. Paul A.V., et al. Biochemical and genetic studies of the VPg uridylylation reaction catalyzed by the RNA polymerase of poliovirus. J. Virol. 2003, 77:891-904.
95. Pevear D.C., et al. Activity of Pleconaril against Enteroviruses. Antimicrob. Agents Chemother. 1999, 43:2109-2115.
96. Phipps K.M., et al. Small interfering RNA molecules as potential anti-human rhinovirus agents: in vitro potency, specificity, and mechanism. Antiviral Res. 2004, 61:49-55.
97. Plevka P., et al. Crystal structure of human enterovirus 71. Science 2012, 7(5):e34589.
98. Pourianfar H.R., et al. In vitro evaluation of the antiviral activity of heparin sulfate mimetic compounds against Enterovirus 71. Virus Res. 2012, 169(1):22-29.
99. Prendergast, P.T., 2001. Use of flavones, coumarins, and related compounds to treat infections. World (PTC) Patent WO-0103681.
100. Racaniello V.R. Picornaviridae: the viruses and their replication. Fields virology 2001, 685-722. Lippencott Williams & Wilkens, Philadelphia. 4th ed. D.M. Knipe, P.M. Howley (Eds.).
101. Racaniello V.R. Picornaviridae: the viruses and their replication. Fields Virology 2007, 796-839. Lippincott Williams & Wilkins, Philadelphia. 5th ed. D.M. Knipe, P.M. Howley (Eds.).
102. Rotbart H.A. Treatment of picornavirus infections. Antiviral Res. 2002, 53:83-98.
103. Ryan M.D., Flint M. Virus-encoded proteinases of the picornavirus super-group. J. Gen. Virol. 1997, 78:699-723.
104. Semler B.L. Molecular Biology of Picornaviruses 2002, American Society for Microbiology, Washington, DC. E. Wimmer (Ed.).
105. Sharma R., et al. Nuclear entry of poliovirus protease-polymerase precursor 3CD: implications for host cell transcription shut-off. Virology 2004, 320:195-205.
106. Shia K.S., et al. Design, synthesis, structure-activity relationship of pyridyl imidazolidinones: a novel class of potent and selective human enterovirus 71 inhibitors. J. Med. Chem. 2002, 45:1644-1655.
107. Shia, K.S., et al., 2003. Imidazolidinone compounds. US Patent US-0087936.
108. Shih S.R., et al. Inhibition of enterovirus71-induced apoptosis by allophycocyanin isolated from a blue-green alga Spirulina platensis. J. Med. Virol. 2003, 70:119-125.
109. Shih S.R., et al. Selective human enterovirus and rhinovirus inhibitors: an overview of capsid-binding and protease-inhibiting molecules. Med. Res. Rev. 2004, 24:449-474.
110. Shih S.R., et al. Design, synthesis, and structure-activity relationships of pyrazolo[3,4-d]pyrimidines: a novel class of potent enterovirus inhibitors. Bioorg. Med. Chem. Lett. 2004, 14:2519-2525.
111. Shih S.R., et al. Mutation in enterovirus 71 capsid protein VP1 confers resistance to the inhibitory effects of pyridyl imidazolidinone. Antimicrob. Agents Chemother. 2004, 48(9):3523-3529.
112. Shih S.R., et al. Viral protein synthesis is required for enterovirus71 to induce apoptosis in human glioblastoma cells. J. Neurovirol. 2008, 14:53-61.
113. Sivasamugham L.A., et al. Recombinant new castle disease virus capsids displaying enterovirus 71 VP1 fragment induce a strong immune response in rabbits. J. Med. Virol. 2006, 78:1096-1104.
114. Sommergruber W., et al. Polypeptide 2A of human rhinovirus type 2: identification as a protease and characterization by mutational analysis. Virology 1989, 169:68-77.
115. Su P.Y., et al. Cell surface sialylation affects binding of enterovirus 71 to rhabdomyosarcoma and neuroblastoma cells. BMC Microbiol. 2012, 12:162.
116. Tan C.S., Cardosa M.J. High-titred neutralizing antibodies to human enterovirus preferentially bind to the N-terminal portion of the capsid protein VP1. Arch. Virol. 2007, 152:1069-1073.
117. Tan C.W., et al. Inhibition of enterovirus 71 (EV-71) infections by a novel antiviral peptide derived from EV-71 capsid protein VP1. PLoS ONE 2012, 7:e34589.
118. Tan X.J., et al. The persistent circulation of Enterovirus 71 in People's Republic of China: causing emerging nationwide epidemics since 2008. PLoS ONE 2011, 6:e25662.
119. Tang W.F., et al. Reticulon 3 binds the 2C protein of enterovirus 71 and is required for viral replication. J. Biol. Chem. 2007, 282:5888-5898.
120. Toyoda H., et al. A second virus-encoded proteinase involved in proteolytic processing of poliovirus polyprotein. Cell 1986, 45:761-770.
121. Tsai M.T., et al. Real-time monitoring of human enterovirus (HEV)-infected cells and anti-HEV 3C protease potency by fluorescence resonance energy transfer. Antimicrob. Agents Chemother. 2009, 53:748-755.
122. Tung W.S., et al. DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet. Vaccines Ther. 2007, 5-6.
123. Urbinati C., et al. Polyanionic drugs and viral oncogenesis: a novel approach to control infection, tumor-associated inflammation and angiogenesis. Molecules 2008, 13:2758-2785.
124. Van Kuppeveld F.J., et al. Coxsackie B3 virus protein 2B contains cationic amphipathic helix that is required for viral RNA replication. J. Virol. 1996, 70:3876-3886.
125. Van Kuppeveld F.J., et al. Coxsackievirus protein 2B modifies endoplasmic reticulum membrane and plasma membrane permeability and facilitates virus release. EMBO J. 1997, 16:3519-3532.
126. Wang B., et al. MEK1-ERKs signal cascade is required for the replication of Enterovirus 71 (EV71). Antiviral Res. 2012, 93:110-117.
127. Wang J., et al. Crystal structure of enterovirus 71 3C protease complexed with rupintrivir reveals the roles of catalytically important residues. J. Virol. 2011, 85:10021-10030.
128. Wang X.X., et al. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat. Struct. Mol. Biol. 2012, 19:424-429.
129. Watson K.G., et al. An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus. J. Med. Chem. 2003, 46:3181-3184.
130. Weidman M.K., et al. Poliovirus 3C protease-mediated degradation of transcriptional activator p53 requires a cellular activity. Virology 2001, 291:260-271.
131. Weng K.F., et al. Enterovirus 71 3C protease cleaves a novel target CstF-64 and inhibits cellular polyadenylation. PLoS Pathog. 2009, 5:e1000593.
132. Weng T.Y., et al. Lactoferrin inhibits enterovirus 71 infection by binding to VP1 protein and host cells. Antiviral Res. 2005, 67:31-37.
133. Wu C.N., et al. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 2001, 20:895-904.
134. Wu Y., et al. Structures of EV71 RNA-dependent RNA polymerase in complex with substrate and analogue provide a drug target against the hand-foot-and-mouth diseasepandemic in China. Protein Cell 2010, 1:491-500.
135. Wu Z., et al. Identification of small interfering RNAs which inhibit the replication of several Enterovirus 71 strains in China. J. Virol. Methods 2009, 159:233-238.
136. Xie S.Q., et al. DIDS blocks a chloride-dependent current that is mediated by the 2B protein of enterovirus 71. Cell Res. 2011, 21:1271-1275.
137. Xue F., et al. Inhibitory properties of 2-substituent-1H-benzimidazole-4-carboxamide derivatives against enteroviruses. Bioorg. Med. Chem. 2011, 19:2641-2649.
138. Pro cleaves the TATA-binding protein but does not inhibit host cell RNA polymerase II transcription in vitro. J. Virol. 1997, 71:6881-6886.
139. pro. J. Virol. 1997, 71:1220-1226.
140. pro. Virology 1997, 239:176-185.
141. Yamayoshi S., et al. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat. Med. 2009, 15:798-801.
142. Yang B., et al. Sialylated glycans as receptor and inhibitor of enterovirus71 infection to DLD-1 intestinal cells. Virol. J. 2009, 6:141-148.
143. Yang Y., et al. Antiviral effect of matrine against human enterovirus 71. Molecules 2012, 17(9):10370-10376.
144. Yi L., et al. Potent inhibition of human enterovirus 71 replication by type I interferon subtypes. Antiviral Ther. 2011, 16(1):51-58.
145. Yorihiro N., et al. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat. Med. 2009, 15:794-797.
146. Zhang G., et al. In vitro and in vivo evaluation of ribavirin and pleconaril antiviral activity against enterovirus 71 infection. Arch. Virol. 2012, 157(4):669-679.
147. Zhang X.N., et al. Rupintrivir is a promising candidate for the treatment severe cases of Enterovirus 71 infection. World J. Gastroenterol. 2010, 16:201-209.
148. Zhang Y., et al. An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of Hand Foot and Mouth Disease in Fuyang city of China. Virol. J. 2010, 7:94.
149. Zheng Z.H., et al. Enterovirus 71 2C protein inhibits INF-α-mediated activation of NF-kB by suppressing IkB kinase β phosphorylation. J. Immunol. 2011, 187:2202-2212.
150. Zheng Z.M., et al. Isolation of enterovirus type 71 from the vesicle fluid of an adult patient with hand-foot-mouth disease in China. Virologica Sinica 1989, 4:375-381.
151. Zhu Q.C., et al. Inhibition of enterovirus 71 replication by chrysosplenetin and penduletin. Eur. J. Pharm. Sci. 2011, 44:392-398.